6280-29-1Relevant academic research and scientific papers
INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
-
Page/Page column 16, (2012/03/10)
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS
-
Page/Page column 16, (2010/11/28)
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers
Vieira, Eric,Huwyler, Joerg,Jolidon, Synese,Knoflach, Frederic,Mutel, Vincent,Wichmann, Juergen
, p. 4628 - 4631 (2007/10/03)
Small molecule mGluR1 enhancers based on the lead compound (9H-xanthene-9-carbonyl)-carbamic acid butyl ester derived from random-screening hit diphenylacetyl-carbamic acid ethyl ester were designed and synthesized as useful pharmacological tools for the study of the physiological roles mediated by mGlu1 receptors. The synthesis and the structure-activity relationship of this new class of positive allosteric modulators of mGlu1 receptors will be discussed in detail.
